FIELD: medicine.
SUBSTANCE: invention can be used in medicine for prevention and treatment of the human Derriere orthologue (protein GDF3) associated diseases, e.g., for progressing on inhibition semenoma and obesity due to an incorrect diet.
EFFECT: invention allows to block signalling pathway activated by TGF-beta factor Derriere in animal cells by the introduction of an effective amount quantity of noggin2 protein in a tissue containing Derriere protein.
2 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF BLOCKING SIGNAL PATH ACTIVATED BY TGF-beta FACTOR OF VgI IN ANIMAL CELLS | 2008 |
|
RU2391352C1 |
| NOGGIN2-BASED ACTIVIN ACTIVITY BLOCKING METHOD | 2005 |
|
RU2354662C2 |
| METHOD FOR SIGNAL PATH BLOCKING ACTIVATED BY Wnt8 FACTORS IN ANIMAL CELLS BY MEANS OF NOGGIN FAMILY PROTEINS | 2011 |
|
RU2473561C1 |
| METHOD OF CULTIVATION PLURIPOTENTIAL STEM CELLS | 2005 |
|
RU2375448C2 |
| DIFFERENTIATION OF HUMAN EMBRYO STEM CELLS | 2008 |
|
RU2473685C2 |
| METHOD FOR PRODUCING POPULATION OF PANCREATIC ENDOCRINE CELLS CO-EXPRESSING NKX6.1 AND INSULIN, AND METHOD OF TREATING DIABETES | 2010 |
|
RU2701335C2 |
| DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | 2010 |
|
RU2610176C2 |
| DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | 2008 |
|
RU2465323C2 |
| DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | 2018 |
|
RU2782271C2 |
| TRANSGENIC MOUSE USED FOR INVESTIGATION OF REPARATIVE REGENERATION OF SKIN WOUND | 2023 |
|
RU2823992C1 |
